Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan

BACKGROUND: An antiemetic triplet regimen of 5-hydrotryptamine-3 receptor antagonist, dexamethasone, and aprepitant is the standard prophylaxis with highly emetogenic chemotherapy (HEC). A randomized phase III trial comparing palonosetron (PALO) versus granisetron (GRA) in the triplet antiemetic reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwa, Munenobu, Matsushita, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604132/
https://www.ncbi.nlm.nih.gov/pubmed/31262292
http://dx.doi.org/10.1186/s12913-019-4281-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604132/
https://www.ncbi.nlm.nih.gov/pubmed/31262292
http://dx.doi.org/10.1186/s12913-019-4281-0

Ejemplares similares